Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation titled “Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema,” published online November 25, 2015, in JAMA Ophthalmology,1 there was an error in Table 3. The change in CST from baseline, mean (SD), µm for aflibercept (n = 61) should have read as follows: “−285 (147).” This article was corrected online.
Error in Table. JAMA Ophthalmol. 2016;134(4):469. doi:10.1001/jamaophthalmol.2016.0428